These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19586497)

  • 1. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
    Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
    J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
    Sriprakash K; Godbolt A
    Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
    Shulstad RM
    Dermatol Nurs; 2009; 21(2):86-7. PubMed ID: 19507375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod.
    Jacob SE; Blyumin M
    Dermatol Surg; 2008 Jun; 34(6):844-5. PubMed ID: 18363730
    [No Abstract]   [Full Text] [Related]  

  • 7. Giant basal cell carcinoma. Improvement and vitiligo-like hypopigmentation after intermittent treatment with 5% imiquimod.
    Urbina F
    Acta Dermatovenerol Croat; 2012; 20(4):275-8. PubMed ID: 23317492
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod.
    Mashiah J; Brenner S
    Clin Exp Dermatol; 2008 Jan; 33(1):74-6. PubMed ID: 17979992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod-induced depigmentation: report of two cases and review of the literature.
    Burnett CT; Kouba DJ
    Dermatol Surg; 2012 Nov; 38(11):1872-5. PubMed ID: 22805097
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
    Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
    Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
    RUIZ-VILLAVERDE R; SANCHEZ-CANO D; BURKHARDT-PEREZ P; SINTES RN
    Eur J Dermatol; 2009; 19(5):481-3. PubMed ID: 19527989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
    Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
    Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
    Vun Y; Siller G
    Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsyndromic multiple basal cell carcinomas successfully treated with imiquimod 5% cream.
    Kocabaş E; Ermertcan AT; Bilaç C; Bilaç DB; Temiz P
    Cutan Ocul Toxicol; 2010 Dec; 29(4):300-2. PubMed ID: 20684662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma.
    Carneiro RC; de Macedo EM; Matayoshi S
    Ophthalmic Plast Reconstr Surg; 2010; 26(2):100-2. PubMed ID: 20305508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.